CARDIOGENESIS REPORTS 2002 FOURTH QUARTER, YEAR END RESULTS
PAGE 3-3-3
Quinn said that CardioGenesis intends to file its annual report on Form 10-K with the
Securities and Exchange Commission on or before March 31, 2003.
Conference Call
CardioGenesis will host a conference call today to discuss the Company's results for the
fourth quarter and year ended December 31, 2002. The call will take place at 1:00 p.m. EST
(Eastern) and will be broadcast live over the Internet. Those interested in listening to the live
webcast of the conference call may do so by going to the Company's website at
www.cardiogenesis.com
.
Web participants are encouraged to go to the website at least 15 minutes prior to the start
of the call to register and, if necessary, download and install any needed audio software. An
online webcast replay of the call will be accessible at
www.cardiogenesis.com
for seven days
starting shortly after the live webcast.
About CardioGenesis Corporation
CardioGenesis is a medical device company specializing in the treatment of
cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The
Company's market leading Holmium: YAG laser system and disposable fiber-optic accessories
are used to perform a FDA-cleared surgical procedure known as transmyocardial
revascularization (TMR) to treat patients suffering from angina. The CardioGenesis TMR
procedure, which is marketed in the U.S. and around the world, has been shown to reduce angina
and improve the quality of life in patients with coronary artery disease. The Company's
minimally invasive percutaneous myocardial revascularization (PMR) procedure is currently
being marketed in Europe and other international markets.
For more information on the Company and its products, please visit the CardioGenesis
web site at
http://www.cardiogenesis.com
. For investor relations information, visit the
CardioGenesis pages in the "Client" section of the Allen & Caron Inc web site at
www.allencaron.com
.
Any forward-looking statements in this news release related to the Company's sales, profitability, the adoption of its
technology and products and FDA clearances are based on current expectations and beliefs and are subject to
numerous risks and uncertainties that could cause actual results to differ materially. Other factors that could cause
CardioGenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's
Annual Report on Form 10-K for the year ended December 31, 2001, its Quarterly Report on Form 10-Q for the
third quarter ended September 30, 2002, and the Company's other recent SEC filings. The Company disclaims any
obligation to update any forward-looking statements as a result of developments occurring after the date of this press
release.
TABLES FOLLOW
